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Abstract With recent medical advances in diagnosis and
treatment, the increasing numbers of long-term survivors of
breast cancer is considerable and has resulted in the expansion
of scientific research to include examination of lifestyle mod-
ifications as means of prevention of recurrence, new breast
cancer events, and mortality. The objective of this report is
to review randomized controlled trials (RCTs) including diet
and/or exercise interventions on breast cancer recurrence in
women with a history of breast cancer as well as pertinent
recent epidemiologic evidence. Implicated biologic mecha-
nisms are discussed to elucidate the impact of diet and exer-
cise on disease recurrence.
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Introduction
Given the recent advances in the diagnosis and treatment of
breast cancer, the number of breast cancer survivors is steadily
growing, with the 5-year relative survival rate of 91 % and
more patients living longer past diagnosis [1]. Yet, with this
greater survival, the long-term effects of breast cancer and
treatment-related side effects have become increasingly evident.
Breast cancer survivors are at higher risk for weight gain follow-
ing diagnosis regardless of menopausal status [2], and given that
obesity is a risk factor for a number of adverse outcomes, includ-
ing comorbid disease, recurrence or overall mortality, research
has expanded to include investigations into lifestyle modifica-
tions directed towards healthy weight management. The lifestyle
modifications aimed at preventing recurrence, typically defined
as a relapse event at a local, regional, or distal site, have consisted
of a healthful diet, nutritional supplements, regular exercise, or
some combination of these components.
Though numerous reviews have been conducted on the
relationship between lifestyle factors and cancer recurrence
[3–6], not all have been specific to breast cancer, focused
primarily on evidence from randomized controlled trials
(RCTs), or discussed the physiological mechanisms underpin-
ning lifestyle modifications in relation to breast cancer recur-
rence. Therefore, the purpose of this review is to summarize
evidence from recent lifestyle interventions examining the
role of diet, exercise, or multicomponent approaches on recur-
rence and mortality outcomes in breast cancer survivors. As
such, this review is organized into three sections: (1) diet
interventions; (2) exercise interventions; and (3) multicompo-
nent approaches involving diet combinedwith exercise. Based
on this body of knowledge, reasonable recommendations on
diet and exercise that aim to reduce the risk of recurrence and
mortality in breast cancer survivors are provided.
Diet and Risk of Breast Cancer Recurrence
Considerable evidence exists for the role of healthy eating in
breast cancer prevention, while the body of support for the
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effects of diet on the risk of breast cancer recurrence is rapidly
growing [3]. This section will focus on diet-only interventions
rather than multicomponent approaches involving both diet
and exercise, which are discussed together in a later section.
Data from randomized controlled trials (RCTs) involving
women with breast cancer are presented in regards to two
primary dietary patterns—(1) a low-fat diet and (2) a low-
fat, high fruit, and vegetable diet—and the effects of soy and
vitamin D intake are also discussed.
Low-Fat Diet and Risk of Breast Cancer Recurrence
Data from large observational studies have suggested an asso-
ciation between higher intake of dietary fat and greater risk of
breast cancer recurrence, particularly in post-menopausal
women [5], motivating investigations to examine the effect
of low-fat dietary interventions on breast cancer recurrence.
The Women’s Intervention Nutrition Study (WINS; n = 2437)
was the first of two large, multicenter RCTs employing a low-
fat dietary intervention to promote relapse-free survival in
women with early-stage breast cancer [7]. The second large-
scale RCT, the Women’s Healthy Eating and Living study
(WHEL; n = 3088), incorporated a high intake of fruits and
vegetables in addition to a low-fat diet [8]; hence, it will be
discussed in the subsequent section. In WINS, women aged
48–79, who had completed conventional primary treatment
for early-stage breast cancer including surgery, radiotherapy,
tamoxifen for estrogen receptor (ER)-positive tumors, and
chemotherapy for ER-negative tumors, were recruited within
1 year of diagnosis. Forty percent (n = 975) were randomized
to the low-fat dietary intervention, where participants reduced
the percentage of calories from fat to 15 %. Control subjects
(n = 1462) received only written dietary guidelines. After a
median of 60 months, only 9.8 % of women in the diet group
had reported a recurrence event compared to 12.4 % of wom-
en in the control group, with a hazard ratio for relapse-free
survival, defined as recurrence at any site, of 0.76 (95 % CI,
0.60 to 0.98; p = .034). As statistically significant weight loss
was observed in the intervention group compared to the con-
trol group (p = .005), the dietary intervention was purported to
lower the risk of recurrence through reductions in body
weight. However, no statistical significance was found for
an intervention effect on overall survival (HR = 0.89; 95 %
CI, 0.65 to 1.21; p = .56), although a follow-up analysis re-
ported a significant overall survival benefit in women with ER
and progesterone receptor (PR) disease (7.5 vs. 18.1 % cumu-
lative mortality, RR 0.41, p = .003, n = 362) [9].
Low-Fat Diet and Risk of Breast Cancer Recurrence:
Plausible Mechanisms
The physiological basis for the relationship between a high-fat
diet and breast cancer recurrence has been attributed to higher
body adiposity and the modulatory effects of dietary fats on
eicosanoid synthesis [10–12]. Higher adiposity is associated
with adverse levels of insulin-like growth factor 1 (IGF-1),
inflammatory markers and sex hormones, all of which may
act to promote tumor development and growth [10]. The role
of IGF-1 and its receptor IGF-1R in the progression of breast
tumors has been demonstrated through multiple breast cancer
models (reviewed in Belardi et al. [13•]). Though activation of
IGF-1R alone is not an oncogenic event, survival of already
differentiated cells is dependent on IGF-1/IGF-1R signaling,
suggesting that the IGF-1 axis is an important factor in tumor
progression [14]. Indeed, high expression of activated IGF-1R
is related to poorer survival in breast cancer patients [15].
However, evidence is lacking on the direct relationship be-
tween circulating IGF-1 as a result of dietary intake and its
effect on IGF-1 axis signaling and tumor progression.
On the other hand, more evidence is available to support
the role of adiposity in the breast cancer progression. The
accumulation of adipose tissue, specifically visceral fat, in-
creases circulating levels of pro-inflammatory cytokines, in-
cluding interleukin-6 (IL-6) and transforming growth factor
beta (TGF-β), and the pro-inflammatory adipokine, leptin,
which are secreted from the adipose tissue itself [16, 17].
Leptin in particular has been shown to promote tumor cell
growth and metastases through activation of numerous signal-
ing pathways [16]. In addition, the resulting state of chronic
inflammation from the systemic induction of pro-
inflammatory cytokines has been shown to contribute to tu-
mor angiogenesis and change to a metastatic phenotype
[17–19]. For example, both IL-6 [19] and TGF-β [17] induce
epithelial-to-mesenchymal transition, a correlate of late-stage
tumor progression in which epithelial cells in breast tissue
dedifferentiate to more malignant cells. Furthermore, in-
creased expression of aromatase, the rate-limiting enzyme that
catalyzes the conversion of androgens to estrogens, has been
observed in the adipose tissue of mammary glands in obese
women with breast cancer [18]. As both adipose tissue and
breast cancer epithelium express aromatase, levels of circulat-
ing estradiol are especially elevated in overweight or obese
women with breast cancer [18]. This has particular clinical
significance for women with ER-positive disease, as increased
aromatase expression has been demonstrated to contribute to
poorer prognosis in obese breast cancer patients [20].
In addition to adiposity, dietary fat is postulated to contrib-
ute to carcinogenesis through the synthesis of certain eicosa-
noids or lipid compounds metabolized from fatty acids that
support tumor growth [12]. In diets high in animal fat, the
abundance of omega-6 fatty acids can be used in the produc-
tion of eicosanoids that promote inflammation and tumor an-
giogenesis. Prostaglandin E2 (PGE2) is the most abundant pro-
inflammatory eicosanoid identified in breast cancer and has
been shown to stimulate tumor cell proliferation through aro-
matase upregulation [21]. As aromatase is encoded by the
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CYP19 gene, PGE2 stimulates CYP19 transcription, increas-
ing aromatase expression and bioavailable estrogen.
Ultimately, this manifests as increased expression of estrogen
receptor target genes [11]. Collectively, these findings provide
evidence for the association between diet-induced adiposity
and the promotion of tumorigenesis, reinforcing targeted re-
ductions in dietary fat intake.
Low-Fat, High Fruit, and Vegetable Diet and Risk
of Breast Cancer Recurrence
Similar to the WINS [7], the WHEL study [8] was driven by
early epidemiological evidence suggesting a lower risk of
breast cancer with a low-fat diet, which the investigators com-
bined with preclinical evidence supporting the anticarcinogen-
ic properties of plant-derived foods [22]. The WHEL study
(n = 3088) recruited women aged 18–70 diagnosed with op-
erable invasive breast carcinoma (AJCC version VI Stage I, II
or III) who had completed surgery and radiotherapy but not
chemotherapy. The intervention group (n = 1537) received
telephone counseling, cooking classes, and a newsletter pro-
moting a daily intake of 5 vegetable servings, 16 oz vegetable
juice, 3 fruit servings, 30 g fiber, and 15–20 % energy from
fat. The comparison group (n = 1551) received written dietary
guidelines of 5 servings of fruit and vegetables. Over the mean
7.3-year follow-up, 16.7 % of women in the intervention
group experienced a recurrence event compared to 16.9 %
of women in the comparison group (adjusted HR = 0.96;
95 % CI, 0.80 to 1.14; p = .63), while 10.1 % of women in
the intervention group died compared to 10.3 % in the com-
parison group (adjusted HR = 0.91; 95 % CI, 0.72 to 1.15;
p = .43). No significant differences in weight as a result of
the intervention were observed.
From these findings, the authors concluded that a low-fat,
high vegetable, and fruit intake diet did not reduce recurrence
events or provide survival benefit to women with early-stage
breast cancer. However, in a secondary analysis of 2967WHEL
participants [23], breast cancer survivors without hot flashes
(HF-negative) in the diet group had 31 % fewer recurrence
events compared to HF-negative women in the comparison
group (adjusted HR = 0.69; 95 % CI, 0.51 to 0.93; p = .02).
The effect was even stronger in HF-negative post-menopausal
women, as a 47 % reduction in risk was identified compared to
HF-negative women in the comparison group. As HFs have
been associated with lower estrogen levels in women undergo-
ing breast cancer therapy, including tamoxifen or aromatase
inhibitors, HF-negative women have been found to have higher
estrogen levels and an increased risk of recurrence [24]. Thus,
the reduced risk of recurrence observed in HF-negative women
in the diet intervention group compared to HF-negative women
in the comparison group was attributed to lower estrogen levels
from the low-fat, high fruit, and vegetable diet [23]. In a third
follow-up analysis of the WHEL data, Thomson et al. [25]
examined the association between cruciferous vegetable intake
and risk of recurrence among tamoxifen users (n = 1765) and
found that women who were in the highest reported vegetable
intake tertile at baseline had overall lower hazard for breast
cancer recurrence (HR = 0.48; 95 % CI 0.32–0.70; p = 0.005).
Low-Fat, High Fruit, and Vegetable Diet and Risk
of Breast Cancer Recurrence: Plausible Mechanisms
The postulated mechanisms underlying a high intake of fruits
and vegetables in reducing the risk of recurrence are related to
the role of plant-derived foods as a source of chemopreventive
compounds and having the ability to lower circulating estro-
gen concentrations. The anticarcinogenic properties of such a
dietary pattern have been attributed to high levels of
phytonutrients, including carotenoids, polyphenols, and iso-
thiocyanates [22]. Preclinical data investigating the cancer-
preventative activity of phytonutrients support this hypothe-
sis, as the carotenoid lycopene was demonstrated to inhibit
IGF-1-induced [26] and estrogen-induced proliferation in
breast cancer cells [27]. Yet, despite evidence for the inhibi-
tory action of phytonutrients on breast cancer cell prolifera-
tion, and observational data supporting an inverse relationship
between phytonutrient consumption and risk of recurrence
[25], phytonutrient interventions demonstrating actual inhibi-
tion of estrogen- and IGF-1 dependent signaling in breast
cancer patients have yet to be conducted.
The second mechanism by which diet composition may in-
fluence disease recurrence and survival is through an effect on
reproductive hormones. A high-vegetable, high-fiber, low-fat
diet intervention has been associated with a significant reduc-
tion in serum estradiol concentrations in women diagnosedwith
early-stage breast cancer, even without loss of body weight
[28]. However, fiber intake was also found to be independently
related to reductions in serum estradiol concentrations, suggest-
ing that increased fiber, rather than decreased fat intake, may
have been responsible for reductions in circulating estrogen in
these breast cancer patients. The biological mechanism
supporting the role of fiber in positive breast cancer outcomes
is related to its ability to bind to estrogen, as fiber supplemen-
tation in female rats with mammary tumors resulted in in-
creased fecal excretion and inhibition of intestinal reabsorption
of estrogen [29]. Taken together, these results suggest a poten-
tially beneficial influence of fiber on breast cancer recurrence
due to reductions in circulating estrogen. However, as no direct
evidence exists to support this conclusion, interpretation of the
epidemiological data is limited.
Soy and Vitamin D Intake and Risk of Breast Cancer
Recurrence
At present, no RCTs have been conducted expressly incorpo-
rating soy or vitamin D as part of a diet intervention; therefore,
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in the proceeding section, observational and preclinical data
are discussed in relation to breast cancer survival.
Conflicting data exists between epidemiological and pre-
clinical investigations on the role of soy intake in breast cancer
recurrence. While the epidemiological data has found no as-
sociation between soy intake and adverse breast cancer events
[30–34], the in vitro and in vivo data have raised concerns on
the safety of phytoestrogens in breast cancer survival. Soy
foods, such as soy milk and tofu, are rich in isoflavones that
are structurally similar to the primary endogenous estrogen
17β-estradiol [32]. A major isoflavone in soy products is ge-
nistein, which can compete for binding to the ER in breast
tissue, although the binding affinity of isoflavones for the
ER is a magnitude lower than that of 17 β-estradiol [35]. As
such, isoflavones have traditionally been regarded as ER mod-
ulators that can exhibit estrogen-like properties, potentially pro-
moting mammary tumorigenesis [30]. However, the concerns
surrounding the relationship between genistein and breast tu-
mor proliferation have been questioned in a recent review, with
evidence cited to support the anticarcinogenic effects of genis-
tein while disputing its stimulatory effects [35]. For example, in
a DMBA (7,12-dimethylbenz[a]anthracene) model of induced
mammary carcinoma, female rats exposed to genistein during
the early neonatal period had reduced incidence of mammary
tumors compared to control rats [36], while in an orthotopic
model of breast cancer, mice who received genistein supple-
mentation exhibited a 10-fold lower metastatic burden com-
pared to control mice [37]. Yet, the authors acknowledge pre-
clinical data reinforcing the stimulatory effect of genistein on
established ER-positive mammary tumors, albeit at a rate lower
to estradiol. In contrast, the epidemiological data unequivocally
refutes the dangers of isoflavones in breast recurrence, with data
from 4 large clinical trials reporting no adverse relationship
between soy intake and breast cancer prognosis [30–32, 34],
and 1 observational trial in fact reporting a statistically signifi-
cant reduced risk of recurrence with a post-diagnosis soy food
consumption ≥10 mg isoflavones/day (HR = 0.75; 95 % CI
0.61–0.92) [33]. Thus, despite the extensive research investi-
gating the adverse effect of isoflavones on mammary tumori-
genesis, it appears from observational data that soy-derived
genistein does not negatively impact breast cancer recurrence,
particularly in ER-negative disease. However, before clinical
guidelines can be proposed, RCTs incorporating soy products
in a dietary intervention are warranted to demonstrate clear
evidence that soy intake is safe and possibly chemopreventive.
Similarly, investigations on the relationship between vita-
min D intake and breast cancer recurrence have been limited
to preclinical and observational data, with additional insight
provided by correlative studies nested in RCTs comprised of
women with early-stage breast cancer. Though evidence from
in vitro, animal, and observational studies support the role of
vitamin D in improving breast cancer outcomes, data from
prospective [38] and observational studies nested randomized
trials [39, 40•, 41] in women with breast cancer have not
suggested prognostic associations [39, 40•, 41]. The physio-
logical mechanism underpinning the inhibitory action of vita-
min D on breast cancer centers on calcitriol, the hormonally
active form of vitamin D. Calcitriol inhibits proliferation of
human breast cancer cell lines and arrests tumor growth in
xenograft models through several processes that ultimately
suppress estrogen pathways in breast cancer cells (reviewed
in Krishnan et al. [42]). Briefly, calcitriol reduces estrogen
synthesis through direct repression of CYP19 and through
decreases in PGE2. In addition to reducing estrogen synthesis,
calcitriol downregulates ERα expression, suppressing the ac-
tion of estrogen. The mechanistic evidence is in agreement
with observational data supporting an adverse association be-
tween breast cancer recurrence and levels of serum 25-
hydroxyvitamin D [25(OH)D], the precursor to calcitriol
[43, 44]. In contrast, findings from observational studies con-
tradict these results, as no associations between serum
25(OH)D levels and breast cancer outcomes have been ob-
served in a secondary analysis of the WHEL data [38], or in
adjuvant (MA.21 [40•], MA.14 [41]) or neo-adjuvant (I-SPY
[39]) settings. Although the nesting of observational studies in
randomized trials such as that in Clark et al. [39], Lohmann et
al. [40•], and Pritchard et al. [41] has its limitations, the RCTs
provide greater standardization of tumor, treatment, and out-
come characterizations than the non-therapeutic observational
studies. Clearly, therapeutic interventions involving vitamin D
supplementation would be desirable in evaluating the effects
of vitamin D on breast cancer outcomes, as neither observa-
tional nor post hoc correlative studies provide substantive ev-
idence on which to base recommendations.
Summary and Current Dietary Recommendations
Though results from the large-scale WHEL and WINS ran-
domized trials do not support an effect of low-fat/high fruit
and vegetable diets on overall survival, evidence from WINS
and a secondary analysis of the WHEL data have potentially
demonstrated a benefit of a reduced-fat diet on risk of recur-
rence. As the positive findings fromWINS and the secondary
analyses of WHEL were associated with weight loss or hor-
monal status, the mechanism by which a reduced-fat diet may
exert its beneficial effects may be mediated through metabolic
hormones and factors associated with decreased adiposity.
Furthermore, although data from randomized trials is lacking,
soy intake does not appear to be adversely related to breast
cancer outcomes nor are low vitamin D levels unequivocally
associated with recurrence or increased mortality. Despite the
limited evidence supporting diet interventions in preventing
breast cancer recurrence, recent recommendations for cancer
survivors from the American Cancer Society (ACS) [6] un-
derscore the growing importance of a healthy diet across the
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continuum of cancer survivorship. As weight gain is a com-
mon occurrence following breast cancer diagnosis, and survi-
vors are at increased risk for comorbid conditions such as
cardiovascular disease and diabetes, achieving a healthy
weight through reductions in caloric intake and increases in
energy expenditure through a combination of diet, exercise,
and behavioral strategies is encouraged (Fig. 1). In general,
the ACS diet recommendations follow guidelines similar to
that of the American Heart Association [45], with a recom-
mended dietary composition of 45–65 % energy from carbo-
hydrate, 10–35 % of energy from protein, and 20–35 % ener-
gy from fat. Reductions in the energy density of the diet by
limiting portions of energy-dense foods, such as high-fat and
sugary items, are emphasized, in addition to increasing intake
of low-energy-dense foods, such as vegetables and fruits.
Furthermore, consuming carbohydrate sources that are rich
in essential nutrients, phytochemicals, and fiber are encour-
aged, while refined grains, such as white bread and white
process, should be avoided. As protein intake is essential dur-
ing all stages of survivorship, the ACS recommends consump-
tion of protein that is low in saturated fat and limited intake of
processed meats. However, not all fat is adverse, as intake of
omega-3 fatty acids from sources like fish or nuts is advised.
In terms of dietary supplements, nutrients should be primarily
obtained through food sources, with supplementation only
considered if a nutrient deficiency is clinically present.
These diet recommendations are summarized in Table 1.
Physical Activity/Exercise and Risk of Breast Cancer
Recurrence
For the purposes of this review, physical activity (PA) is de-
fined as any movement requiring energy expenditure, while
exercise is PA that is planned, structured, and directed to
enhancing physical fitness and health [4]. BPA^ will be used
when referencing epidemiologic studies and Bexercise^ when
referring to RCTs.
An increased risk of breast cancer recurrence in breast can-
cer survivors (∼34 %) compared to physically active breast
cancer survivors has been, in part, attributed to sedentary life-
style behaviors [46]. Since exercise has been shown to elicit
numerous health benefits including improved quality of life,
increased physical functioning, reduced cancer-related fatigue
as well as reductions in obesity-related comorbidities in cancer
survivors [47–49], the plausible effects of exercise on breast
cancer recurrence are important to consider. Although there
have been efforts to ameliorate the side effects breast cancer-
related treatments with increased aerobic and resistance exer-
cise [50–52], the evidence is lacking to provide information
on the effects of exercise on breast cancer recurrence. This
section presents evidence from both epidemiological and clin-
ical trials examining the effect of PA or exercise on breast
cancer recurrence outcomes. In addition, possible mechanisms
elucidating the relationship between PA/exercise and disease
recurrence will be discussed.
PA and Risk of Breast Cancer Recurrence: Epidemiologic
Evidence
Previously published review articles have summarized the ef-
fects of PA on breast cancer events and mortality [3, 5, 53],
including the recent systemic review summarized here [54•].
This systemic review and meta-analysis included 22 prospec-
tive studies and, in brief, found an inverse relationship be-
tween PA and all-cause, breast cancer-related death and breast
cancer events (i.e., recurrence). For example, compared to
those who reported low/no lifetime recreational pre-
diagnosis PA, women who reported high lifetime recreational
pre-diagnosis PA levels had a significantly lower risk of all-
cause (HR = 0.82, 95 % CI 0.70–0.96, p < 0.05) and breast
cancer-related death (HR = 0.73, 95 % CI 0.54–0.98, p <
0.05). Significant risk reductions for all-cause and breast
cancer-related death was observed for more recent (≤12 years)
pre-diagnosis recreational PA (HR = 0.73, 95% CI 0.65–0.82,
p < 0.001; and HR = 0.84, 95 % CI 0.73–0.97, p < 0.05, re-
spectively), post-diagnosis PA (HR = 0.52, 95 % CI 0.43–
0.64, p < 0.01; and HR = 0.59, 95 % CI 0.45–0.78, p < 0.05,
respectively), and meeting recommended PA guidelines (i.e.,
≥8 MET-h/week; MET or metabolic equivalent, is a concept
used to express the energy cost of physical activities as a
multiple of resting metabolic rate where 1 MET if the amount
of oxygen consumed while sitting at rest) post-diagnosis
(HR = 0.54, 95 % CI 0.38–0.76, p < 0.01; and HR = 0.67,
95 % CI 0.50–0.90, p < 0.01, respectively). Pre-diagnosis
(lifetime and more recent combined) and post-diagnosis PA
were associated with reduced risk of breast cancer events
(breast cancer progression, new primaries and recurrence
Fig. 1 Plausible mechanisms mediating the impact of diet and exercise
on breast cancer recurrence. IGF-1 insulin-like growth factor-1
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combined) (HR = 0.72 95 % CI 0.56–0.91, p < 0.01; and
HR = 0.79, 95 % CI 0.63–0.98, p < 0.05, respectively).
Thus, the authors suggest this evidence supports the notion
that exercise is an important consideration for reducing these
events in breast cancer survivors.
One of the hallmark epidemiological studies to establish
the association of PA and survival after breast cancer diagno-
sis was the Nurses’ Health Study [55]. This prospective ob-
servational study examined breast cancer mortality risk ac-
cording to PA category (<3, 3–8.9, 9–14.9, 15–23.9, or 24
metabolic equivalent task [MET] hours per week) and includ-
ed 2987 women diagnosed with stage I–III breast cancer.
When compared with women who engaged in <3 MET-h/
week of PA, the adjusted RR of death from breast cancer
was 0.80 (95 % CI, 0.60–1.06) for 3–8.9 MET-h/week; 0.50
(95 % CI, 0.31–0.82) for 9–14.9MET-h/week; 0.56 (95 % CI,
0.38–0.84) for 15–23.9 MET-h/week; and 0.60 (95 % CI,
0.40–0.89) for 24 or more MET-h/week (Ptrend = .004). PA
was particularly beneficial among women with hormone-
responsive tumors where the RR of breast cancer death for
women with hormone-responsive tumors who engaged in ≥9
MET-h/week of PA compared with women with hormone-
responsive tumors who engaged in <9 MET-h/week was 0.50
(95 % CI, 0.34–0.74). The absolute unadjusted mortality risk
reduction was 6 % at 10 years for women who engaged in ≥9
MET-h/week when compared with women who engaged in <3
MET-h/week of PA. The authors concluded that PA after breast
cancer diagnosis may reduce the risk of death from the disease,
with the greatest benefit observed in womenwho performed the
equivalent of walking 3–5 h/week at an average pace (2–
2.9 mph). Thus, breast cancer survivors who participate in reg-
ular exercise may improve their survival.
In summary, epidemiological evidence supports the partic-
ipation in PA before and after breast cancer diagnosis as a
contributing factor in decreasing risk of breast cancer recur-
rence and mortality. Future clinical trials are warranted to es-
tablish the underlying mechanisms as purported below.
Exercise and Risk of Breast Cancer Recurrence: Evidence
from Clinical Trials
The effect of exercise on breast cancer recurrence is an area
currently under much speculation yet evidence from RCTs is
lacking. However, pertinent to this area is the Supervised Trial
of Aerobic versus Resistance Training (START) multicenter
Canadian RCTwhich recently reported an exploratory analy-
sis of follow-up cancer outcomes in breast cancer survivors
[56••]. The START trial randomized 242 breast cancer survi-
vors to usual care, supervised aerobic, or resistance training
while undergoing adjuvant chemotherapy. For this analysis,
the 2 exercise groups were combined (n = 160) to examine the
effect on disease-free survival (DFS). Eight-year DFS was
lower for the exercise groups (82.7 %) compared with the
usual care group (75.6 %; HR, 0.68: 95 % CI, 0.37–1.24;
log-rank, P = 0.21). Subgroup analyses resulted in potentially
stronger effects of exercise on DFS for women who were
overweight/obese (HR, 0.59: 95 % CI, 0.27–1.27), had stage
II/III cancer (HR, 0.61: 95 % CI, 0.31–1.20), estrogen
Table 1 Diet and exercise
recommendations for breast
cancer survivors implicated to
target reduced risk of recurrence [6]
Diet recommendations Exercise recommendations
Dietary composition
•Carbohydrate: 45–65 % of energy
•Protein: 10–35 % of energy
•Fat: 10–35 % of energy
Carbohydrate
•Eat whole grains and legumes rich in




•Eat protein low in saturated fat
•Avoid processed meats
Fat
•Eat foods rich in omega-3 fatty acids
Dietary supplements
•Obtain nutrients from food sources
•Consider supplements if a nutrient
deficiency is clinically present
Aerobic exercise
•150 min per week of moderate intensity
OR
•75 min per week of vigorous intensity
Resistance exercise
•Include all major muscle groups at least 2 days per week
•Increase intensity progressively over time under the
supervision of a trained exercise specialist
•Use of compression garments are recommended per guidance
from a healthcare professional
Adults older than 65 years
•Follow above recommendations
•Exercise as allowed by their abilities when chronic conditions
exist
•Avoid long periods of physical inactivity
Examples of aerobic exercise by intensity:
•Moderate—walking briskly, biking on level ground, doubles
tennis, water aerobics, ballroom dancing
•Vigorous—hiking uphill, jogging, running, lap swimming,
singles tennis, jumping rope
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receptor-positive tumors (HR, 0.58: 95 % CI, 0.26–1.29), hu-
man epidermal growth factor receptor 2-positive tumors (HR,
0.21: 95 % CI, 0.04–1.02), received taxane-based chemother-
apies (HR, 0.46: 95 % CI, 0.19–1.15), and completed ≥85 %
planned chemotherapy (HR, 0.50: 95 % CI, 0.25–1.01). This
is the first randomized data, to our knowledge, to suggest the
addition of exercise to standard chemotherapy as a means to
improve breast cancer outcomes and a Phase III trial is war-
ranted to further investigate this area.
In addition to the START trial, our laboratory is currently
conducting an RCT to investigate the effects of a 16-week
supervised combined aerobic and resistance exercise interven-
tion on metabolic syndrome and DFS in overweight/obese
breast cancer survivors who completed chemotherapy and/or
radiation within the prior 6 months [57]. Although the main
outcomes of this study include metabolic syndrome and relat-
ed cardio-metabolic outcomes, a follow-up analysis is includ-
ed to assess DFS annually for 10 years after completion of the
intervention. This ongoing RCTcurrently has 79 breast cancer
survivors enrolled (as of March 2016), and we seek to enroll a
total of 200 women for our DFS analysis. We hope this inves-
tigation contributes to the exploratory hypothesis that exercise
may affect breast cancer prognosis.
PA and Exercise and Risk of Breast Cancer Recurrence:
Plausible Mechanisms
The physiological mechanisms through which physical activity
may influence risk of breast cancer recurrence relate to the
effect of exercise on adipose tissue and skeletal muscle [58]
and is summarized in Fig. 1. By targeting adiposity, exercise
may reduce adverse outcomes associated with fat accumulation
including an altered hormonal environment and overexpressed
adipokine production, both of which may act to promote tumor
development and growth [10]. In addition, increases in skeletal
muscle as a result of exercise may reduce insulin resistance, a
common comorbidity in obese individuals [59].
Metabolic hormones are adversely affected by adiposity,
with detrimental alterations observed in insulin and IGF-1.
Unfavorable changes in the hormonal milieu provide an opti-
mal environment for breast cancer cell growth, as insulin and
IGF-1 have been shown to promote tumor development and
metastases via signaling through their receptors [13•]. In ad-
dition, insulin and IGF-1 increase levels of bioavailable estro-
gen via aromatase activity in adipose tissue and through re-
ductions in circulating concentrations of sex hormone binding
globulin (SHBG), a protein that binds to estrogen to decrease
its bioavailability [60]. To date, 4 RCTs utilizing exercise in-
terventions with metabolic hormones as primary endpoints
have been conducted in breast cancer survivors [61–64], yet
only 3 have demonstrated that chronic exercise training can
improve insulin [63] or IGF-1 levels [61, 62], even in the
absence of fat loss [63]. One possible explanation for the
differences in efficacy between Schmitz et al. [64] and the 3
interventions can be attributed to exercise prescription, as the 3
interventions met the American College of Sports Medicine
(ACSM)/ACS exercise recommendation for cancer survivors
of at least 150 min/week of moderate intensity exercise or
75 min/week of vigorous intensity exercise [6]. In addition,
the 3 interventions employed aerobic training (AT), with
Ligibel et al. [63] utilizing a combined program of AT and
resistance training (RT), while Schmitz et al. [64] employed
only RT. Another explanation for differing results between the
investigations is the enrollment of sedentary, obese breast can-
cer survivors in the studies of Irwin [62] and Ligibel [63] com-
pared to the leaner and more active women in Schmitz’s study.
Baseline concentrations of insulin were lower in Schmitz’s par-
ticipants; hence, exercise interventions may have greater effect
in less active breast cancer survivors with higher adiposity. Yet,
Schmitz et al. also reported significant increases in skeletal
muscle following RT, which conceivably could contribute to
improvements in whole-body glucose tolerance and insulin re-
sistance [59]. However, Schmitz et al. observed no changes in
insulin resistance following RT, suggesting that future exercise
interventions in breast cancer survivors should incorporate
higher intensities, greater volume or employ AT in addition to
RT to elicit optimal changes in cardio-metabolic variables.
While increased concentrations of insulin and IGF-1 may
affect estrogen levels, as previously discussed in the diet sec-
tion, bioavailable estrogen is also independently influenced by
adiposity. Elevated levels of circulating estrogens have been
attributed to excess adipose tissue and increased expression of
aromatase, the enzyme that catalyzes estrogen synthesis, in the
breast tissue of obese breast cancer survivors [18]. As estro-
genic stimulation has been shown to promote tumorigenesis
and breast cancer pathogenesis, higher adiposity has been
suggested to contribute to poorer prognosis in obese breast
cancer patients [20]. Exercise may favorably alter bioavailable
estrogen through either mechanism, although separating the
effects of fat loss from reductions in insulin/IGF-1 due to
exercise has not yet been elucidated in breast cancer survivors.
Rock et al. [60] demonstrated significant reductions in bio-
available estrogen in post-menopausal breast cancer survivors
following a combined physical activity and diet intervention.
As this finding was observed alongside significant weight loss
of 5 %, increased SHBG, and decreased insulin and leptin
concentrations, the authors hypothesized that the reductions
in estrogen were likely mediated by fat loss.
Leptin alone has been associated with a more aggressive
tumor type in post-menopausal breast cancer survivors with
ER-positive disease [65]. As leptin is secreted from white
adipose tissue, higher circulating levels have been observed
in overweight/obese breast cancer survivors compared to lean
patients [66••]. Leptin promotes the recruitment of macro-
phages, which in turn, release pro-inflammatory cytokines,
contributing to a chronic state of systemic inflammation that
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has been purported to correlate with poorer prognosis in breast
cancer survivors [67]. As such, an intervention that reduces
adiposity would be expected to decrease leptin concentrations
alone or in combination with reductions in macrophage-
produced inflammatory cytokines. Evidence supporting the
use of exercise training in lowering leptin concentrations in
breast cancer survivors is emerging, with one RCT demon-
strating significant improvements in leptin in overweight
breast cancer survivors following a 3-month intervention of
150 min/week of exercise, although non-significant changes
were observed in the inflammatory markers IL-6, tumor ne-
crosis factor (TNF)-α, and IL-10 [67]. This finding suggests
that leptin levels in breast cancer survivors are responsive to
exercise, and if leptin is indeed related to recurrence, then
exercise may be a useful therapeutic in improving breast can-
cer outcomes. Future investigations are needed to determine
the role of exercise and its potential mechanisms in favorably
altering adipokine concentrations in breast cancer survivors.
Summary and Current Exercise Recommendations
Epidemiological evidence supports the participation in PA
before and after breast cancer diagnosis as a contributing fac-
tor in decreasing risk of breast cancer recurrence and mortal-
ity. Supportive data from RCTs to promote exercise as a
means to reduce disease recurrence is lacking; however, prom-
ising data from the sole RCT reviewed here examining the
effects of exercise on disease outcomes [56] suggests that
there may be beneficial effects of exercise on breast cancer
recurrence. Additional RCTs are necessary to guide specific
exercise recommendations to target disease recurrence.
Current recommendations set forth by ACSM [68], ACS
[69], and the US Department of Health and Human Services
[70] (Table 1) encourage cancer survivors to follow exercise
prescription for healthy age-matched adults (aged 18–
64 years) which includes 150 min per week of moderate or
75 min per week of vigorous aerobic exercise. Muscle-
strengthening activities or resistance exercise involving all
major muscle groups should be performed 2 days per week;
however, these exercises should be led by a trained exercise
specialist to ensure the intensity is progressed appropriately.
Use of compression garments during exercise is recommend-
ed per guidance from a healthcare professional.
Combined Diet and PA and Risk of Breast Cancer
Recurrence
Due to the independent physiologic effects of diet and phys-
ical activity on adiposity, inflammation, and hormonal regu-
lation, a more potent stimulus to target breast cancer recur-
rence may involve a combined diet and physical activity
intervention. In this section, we will discuss the few clinical
[71••, 72, 73] and epidemiologic [74] investigations assessing
a combined diet and physical activity intervention on breast
cancer recurrence or survival.
Combined Diet and PA and Risk of Breast Cancer
Recurrence: Epidemiologic Evidence
Although the focus of this manuscript is on lifestyle interven-
tion effects on breast cancer recurrence, it is important to rec-
ognize a hallmark epidemiologic study including combined diet
and PA as it influences mortality due to the long-term observa-
tions afforded by this study. This includes the WHEL study [8]
previously mentioned in the diet portion of this review that will
be expanded upon here as it pertains to diet and PA [74].
The WHEL is a prospective cohort study including 1490
women treated for early-stage breast cancer between 1991 and
2000 who enrolled approximately 2 years post-diagnosis.
Interactions between lifestyle factors and mortality were exam-
ined. Dietary patterns were assessed at baseline using 2 24-h
dietary recalls on random days during a 3-week period using a
telephone-based dietary assessment with associated analysis soft-
ware. PA was assessed at baseline using a 9-item questionnaire
on usual PA with queries on frequency, duration, and intensity
used to determine metabolic equivalent (METs) values.
Importantly, reduced mortality was weakly associated with
higher fruit and vegetable consumption (p = 0.02), increased
PA (p= 0.02), and normal BMI (p = 0.06). Using a Cox multi-
variate model, the combination of consuming 5 or more daily
servings of fruits and vegetables, and accumulating 540+ MET
tasks-min/week (or walking 30min 6 days/week) was associated
with improved survival (HR= 0.56; 95 % CI, 0.31 to 0.98, p =
0.04). Notably, the approximate 50% reduced risk was observed
in both obese and non-obese women. Univariate analysis dem-
onstrated that high fruit and vegetable intake and high PA levels
were advantageous on survival for hormone receptor-positive
cancers (ER-positive, PR-negative; p = 0.04; ER-positive, PR-
positive; p= 0.01). The latter result suggests the mechanism of
action may involve reproductive gonadal hormones as previous-
ly suggested for diet and PA lifestyle factors on prognosis.
Despite the observational nature of the WHEL study, it
emphasizes the relation between lifestyle factors and disease
prognosis in a large cohort of women with early-stage breast
cancer. These results have since been used to implement in-
tervention trials as will be discussed in the subsequent section.
Combined Diet and PA and Risk of Breast Cancer
Recurrence: Evidence from Clinical Trials
As obesity is a major risk factor breast cancer recurrence and
morbidity in pre- and post-menopausal women [5, 75, 76],
targeting reductions in body weight through combined diet and
exercise interventions have been conducted. Three RCTs will be
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discussed, including the Exercise and Nutrition to Enhance
Recovery and Good Health for You (ENERGY) trial [71••], a
smaller yet pertinent RCT from Scott and colleagues [72], and an
ongoing RCT—the Diet and Androgens (DIANA)-5 study [73].
The ENERGY trial is the largest weight loss intervention
trial among breast cancer survivors to date [71••]. This multi-
center trial included 692 overweight/obese women who were
approximately 2 years from primary treatment for early-stage
breast cancer. Women were randomized to either a group-
based behavioral intervention with telephone counseling and
newsletters to support weight loss or a less intensive control
intervention including weight management resources and ma-
terials. The goal of the intervention was a 7 % weight loss in
2 years and included weekly 1-h group sessions for the first
4 months tapering to every other week for 2 months followed
by monthly from month 6 onward. Dietary guidance promot-
ed a reduction in energy intake of 500–1000 kcal/day and a PA
goal of an average of 60min/day at a moderate intensity. Body
weight was measured at 6, 12, 18, and 24 months.
At 12 months, the intervention group experienced a mean
weight loss of 6.0 % of initial weight compared to 1.5 % in the
control group (p < .001). At 24 months, the group differences
remained significant (p < .001) with mean weight loss of 3.7
and 1.3 % for the intervention and control groups, respective-
ly. This finding implies that a behavioral weight loss interven-
tion can result in clinically meaningful weight loss in this
population. Although the authors are unable to report the ef-
fect of the intervention on recurrence and survival at this point
in time, they report that a 4–6 % weight loss substantially
reduces circulating levels of estrogens and cytokines, which
are implicated mediators of breast cancer recurrence.
Scott et al. (2013) examined the effects of a diet and PA
intervention on body weight in overweight breast cancer survi-
vors in an effort to determine the relationship between body
weight and biomarkers associated with disease recurrence and
survival [72]. Ninety women treated for early-stage breast can-
cer in the previous 3–18months were randomly assigned to a 6-
month exercise and hypocaloric healthy eating program or con-
trol group. The physical activity portion included 3 weekly 30-
min aerobic exercise (65–85 % age-predicted heart rate maxi-
mum) sessions followed by 10–15min of muscle-strengthening
exercises using resistance bands, hand weights and stability
balls under supervision. The dietary intervention included
one-on-one individualized dietary advice and written informa-
tion pertaining to portion sizes and a healthy eating plan. The
goal of the dietary intervention was a reduction in total daily
caloric intake by 600 kcal from their calculated energy require-
ments. Collectively, the authors purported that this intervention
would result in an estimated weight loss of up to 0.5 kg/week.
The intervention resulted in moderate weight loss (median
difference from baseline of −1.09 kg; p = 0.07) in the interven-
tion group and a significant reduction inwaist circumference (p
< 0.001). Biomarkers associated with long-term prognostic
outcomes of breast cancer including leptin (p = 0.005), total
cholesterol (p = 0.046), and HDL (p = 0.015) were significantly
altered. Positive changes in leptin and total cholesterol were
significantly associated with reductions in body weight and
waist circumference (p < 0.01; R values not reported by au-
thors). The authors concluded that a 6-month exercise and
hypocaloric eating program positively impacted health out-
comes (i.e., weight, waist circumference, leptin) that influence
long-term prognosis in overweight breast cancer survivors.
These 2 RCTs provide strong implications for the impact of
combined diet and exercise on breast cancer recurrence with
the ENERGY trial relying on home-based interventions and
Scott’s trial including supervised, clinic setting interventions.
Both trials did not directly assess survival rates yet rather
measured outcomes strongly linked to prognosis such as cen-
tral adiposity, sex hormones, lipid profiles, and pro-
inflammatory biomarkers, which have been discussed previ-
ously in this manuscript. Each trial provides evidence of
strong effects of a combined intervention on weight loss with
their respective study designs, thus implicating the need for
future RCTs with long-term follow-up assessments to link
these changes with disease recurrence.
A notable ongoing RCT is the Diet and Androgens
(DIANA)-5 study, which is a multicenter RCT examining
the effectiveness of a Mediterranean diet and PA intervention
on breast cancer events between 2008 and 2010, followed
through 2015 [73]. The intervention consists of a counseling
program with cooking classes, exercise sessions, and reinforc-
ing meetings and print materials. The PA goals are to partici-
pate in a moderate intensity PA program of 210 min/week (2–
5 METs) over at least 3 days/week and to decrease sedentary
behavior by 30 min/day on at least 5 days/week. During the
first 12 months, 1 group PA session/month is offered to in-
crease PA adoption. The diet program focuses on reducing
glycemic and insulinemic responses through (1) moderate ca-
loric restriction through increased consumption of highly
satiating foods (refined cereals, legumes, and vegetables),
(2) reduced consumption of high glycemic index food, (3)
reduced consumption of saturated fat, and (4) reduced protein
intake, particularly animal protein (except fish). Outcomes
include recurrence, death from breast cancer, and death from
any cause. The investigators seek to establish a comprehen-
sive lifestyle modification to increase breast cancer event-free
survival. The results of such a trial may be the first to establish
breast cancer outcomes affected by a diet and PA intervention.
Summary
Despite the lack of concrete epidemiologic and clinical evi-
dence supporting the effects of combined diet and PA lifestyle
modifications on breast cancer recurrence, the aforementioned
studies emphasize the benefits of such behaviors on health
Curr Breast Cancer Rep (2016) 8:139–150 147
outcomes biologically linked to recurrence. Further, these
studies shed light on the need to study diet and exercise inter-
ventions moving forward to specifically define parameters to
guide the adoption of lifestyle behaviors targeting disease-free
survival. In the interim, dietary and exercise guidelines
outlined in Table 1 provide a comprehensive foundation that
breast cancer survivors can rely upon to adopt a healthier
lifestyle during survivorship.
Conclusions
In evaluating evidence from RCTs involving diet, exercise, or
combined diet and exercise interventions, the most consistent
finding was that reductions in adiposity accompanied the most
beneficial changes in breast cancer outcomes, including sur-
vival, risk of recurrence, or biomarkers associated with prog-
nosis. These data suggest that body composition is a crucial,
modifiable risk factor for breast cancer prognosis, and inter-
ventions targeting fat loss and skeletal muscle gain may yield
improvements that translate to clinically meaningful out-
comes. While data from currently conducted RCTs is still
emerging, a combined intervention of diet and exercise ap-
pears to hold the most promise in modifying the incidence
of additional breast cancer events or mortality and is also
reinforced by epidemiological evidence. Yet, the lack of con-
clusive evidence supporting whether exercise- or diet-induced
changes can occur independent of changes in fat mass neces-
sitates future work examining the complex interaction be-
tween adiposity, energy balance, and breast cancer recurrence.
Regardless, the data evaluated in this review support the use of
both dietary modification and increased exercise as a means of
improving overall health and reducing risk of recurrence and
mortality in breast cancer survivors.
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